Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against parkinson disease

Prion

Volumn 7, Issue 2, 2013, Pages 121-126

  Park, Sang Myun ^a   Kim, Kwang Soo ^a  

^a Center for Chronic Metabolic Disease Research   (South Korea)

Author keywords

synuclein; Aggregation prone proteins; Matrix metalloproteinase; Neurodegenerative disease; Neurosin; Parkinson disease; Plasmin; Prion; Protease; Proteolysis

Indexed keywords

ALPHA SYNUCLEIN;

AMYLOID PLAQUE; CELL SPREADING; DEGENERATIVE DISEASE; ENDOCYTOSIS; EXCITOTOXICITY; EXOCYTOSIS; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW;

Α-SYNUCLEIN; AGGREGATION-PRONE PROTEINS; MATRIX METALLOPROTEINASE; NEURODEGENERATIVE DISEASE; NEUROSIN; PARKINSON DISEASE; PLASMIN; PRION; PROTEASE; PROTEOLYSIS;

ALPHA-SYNUCLEIN; ANIMALS; DRUG DELIVERY SYSTEMS; EXTRACELLULAR SPACE; HUMANS; PARKINSON DISEASE; PRIONS; PROTEOLYSIS;

EID: 84875443075     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.22850     Document Type: Review

References (98)

1. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010; 11:155-9; PMID:20029438.
2. Saiki S, Sato S, Hattori N. Molecular pathogenesis of Parkinson's disease: update. J Neurol Neurosurg Psychiatry 2012; 83:430-6; PMID:22138181; http://dx.doi.org/10.1136/jnnp-2011-301205.
3. Surguchov A. Chapter 6 Molecular and Cellular Biology of Synucleins. 2008; 270:225-317.
4. Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet 2011; 12:301-25; PMID:21639795; http://dx.doi.org/10.1146/annurev-genom-082410-101440.
5. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41:1303-7; PMID:19915576; http://dx.doi.org/10.1038/ng.485.
6. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41:1308-12; PMID:19915575; http://dx.doi.org/10.1038/ng.487.
7. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol 2011; 10:1015-25; PMID:22014436; http://dx.doi.org/10.1016/S1474-4422(11)70213- 7.
8. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003; 17:1945-7; PMID:14519670.
9. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011; 10:230-40; PMID:21317042; http://dx.doi.org/10.1016/S1474- 4422(11)70014-X.
10. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010; 75:1766-72; PMID:20962290; http://dx.doi.org/10.1212/WNL.0b013e3181fd613b.
11. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005; 25:6016-24; PMID:15976091; http://dx.doi.org/10.1523/JNEUROSCI.0692-05.2005.
12. Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ. Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem 2010; 113:1263-74; PMID:20345754.
13. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 2010; 30:6838-51; PMID:20484626; http://dx.doi.org/10.1523/JNEUROSCI.5699-09. 2010.
14. Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, Wood MJ. Alpha-synuclein release by neurons activates the inf lammatory response in a microglial cell line. Neurosci Res 2011; 69:337-42; PMID:21255620; http://dx.doi.org/10.1016/j.neures.2010.12.020.
15. Sung JY, Kim J, Paik SR, Park JH, Ahn YS, Chung KC. Induction of neuronal cell death by Rab5Adependent endocytosis of alpha-synuclein. J Biol Chem 2001; 276:27441-8; PMID:11316809; http://dx.doi.org/10.1074/jbc.M101318200.
16. Ahn KJ, Paik SR, Chung KC, Kim J. Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. J Neurochem 2006; 97:265-79; PMID:16524375; http://dx.doi.org/10.1111/j.1471-4159. 2006.03731.x.
17. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 2008; 40:1835-49; PMID:18291704; http://dx.doi.org/10.1016/j.biocel.2008. 01.017.
18. Park JY, Kim KS, Lee SB, Ryu JS, Chung KC, Choo YK, et al. On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft. J Neurochem 2009; 110:400-11; PMID:19457104; http://dx.doi.org/10.1111/j.1471-4159.2009.06150.x.
19. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 1998; 440:71-5; PMID:9862428; http://dx.doi.org/10.1016/S0014-5793(98)01418-5.
20. Seo JH, Rah JC, Choi SH, Shin JK, Min K, Kim HS, et al. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J 2002; 16:1826-8; PMID:12223445.
21. Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL. Alpha-synuclein and its diseasecausing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J 2006; 20:2000-8; PMID:17012252; http://dx.doi.org/10.1096/fj.06-6183com.
22. Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, Kim WK, et al. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of proteaseactivated receptor-1. J Immunol 2010; 185:615-23; PMID:20511551; http://dx.doi.org/10.4049/jimmunol. 0903480.
23. Lee SB, Park SM, Ahn KJ, Chung KC, Paik SR, Kim J. Identification of the amino acid sequence motif of alpha-synuclein responsible for macrophage activation. Biochem Biophys Res Commun 2009; 381:39-43; PMID:19351591; http://dx.doi.org/10.1016/j.bbrc.2009.02.002.
24. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005; 19:533-42; PMID:15791003; http://dx.doi.org/10.1096/fj.04-2751com.
25. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14:504-6; PMID:18391962; http://dx.doi.org/10.1038/nm1747.
26. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-tograft disease propagation. Nat Med 2008; 14:501-3; PMID:18391963; http://dx.doi.org/10.1038/nm1746.
27. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197-211; PMID:12498954; http://dx.doi.org/10.1016/S0197-4580(02) 00065-9.
28. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009; 106:13010-5; PMID:19651612; http://dx.doi.org/10.1073/pnas.0903691106.
29. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 2009; 106:20051-6; PMID:19892735.
30. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72:57-71; PMID:21982369; http://dx.doi.org/10.1016/j.neuron.2011.08.033.
31. Hansen C, Angot E, Bergström AL, Steiner JA, Pieri L, Paul G, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121:715-25; PMID:21245577; http://dx.doi.org/10.1172/JCI43366.
32. Kordower JH, Dodiya HB, Kordower AM, Terpstra B, Paumier K, Madhavan L, et al. Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis 2011; 43:552-7; PMID:21600984; http://dx.doi.org/10.1016/j.nbd.2011.05.001.
33. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchère J, Lakhdar L, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012; 33:2225-8; PMID:21813214; http://dx.doi.org/10. 1016/j.neurobiolaging. 2011.06.022.
34. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006; 129:3035-41; PMID:17012293; http://dx.doi.org/10.1093/brain/awl269.
35. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61:1828-34; PMID:8228996; http://dx.doi.org/10.1111/j.1471- 4159.1993.tb09823.x.
36. Chai X, Dage JL, Citron M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis 2012; 48:356-66; PMID:22668776; http://dx.doi.org/10.1016/j.nbd.2012.05.021.
37. Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 2012; 287:3842-9; PMID:22057275; http://dx.doi.org/10.1074/jbc.M111.277061.
38. Simón D, García-García E, Royo F, Falcón-Pérez JM, Avila J. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett 2012; 586:47-54; PMID:22138183; http://dx.doi.org/10.1016/j.febslet.2011.11.022.
39. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009; 284:12845-52; PMID:19282288; http://dx.doi.org/10.1074/jbc.M808759200.
40. Gómez-Ramos A, Díaz-Hernández M, Cuadros R, Hernández F, Avila J. Extracellular tau is toxic to neuronal cells. FEBS Lett 2006; 580:4842-50; PMID:16914144; http://dx.doi.org/10.1016/j.febslet. 2006.07.078.
41. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11:909-13; PMID:19503072; http://dx.doi.org/10.1038/ncb1901.
42. Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 2011; 286:15317-31; PMID:21372138; http://dx.doi.org/10.1074/jbc. M110.209296.
43. Zetterström P, Andersen PM, Brännström T, Marklund SL. Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients. J Neurochem 2011; 117:91-9; PMID:21226712; http://dx.doi.org/10.1111/ j.1471-4159.2011.07177.x.
44. Mondola P, Annella T, Santillo M, Santangelo F. Evidence for secretion of cytosolic CuZn superoxide dismutase by Hep G2 cells and human fibroblasts. Int J Biochem Cell Biol 1996; 28:677-81; PMID:8673732; http://dx.doi.org/10.1016/ 1357-2725(96)00004-0.
45. Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, Julien JP. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 2006; 9:108-18; PMID:16369483; http://dx.doi.org/10.1038/nn1603.
46. Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien JP, et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 2010; 58:231-43; PMID:19672969; http://dx.doi.org/10.1002/glia.20919.
47. Chia R, Tattum MH, Jones S, Collinge J, Fisher EM, Jackson GS. Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis. PLoS One 2010; 5:e10627; PMID:20498711; http://dx.doi.org/10.1371/journal.pone.0010627.
48. Münch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A 2011; 108:3548-53; PMID:21321227; http://dx.doi.org/10.1073/pnas.1017275108.
49. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009; 11:219-25; PMID:19151706; http://dx.doi.org/10.1038/ncb1830.
50. Miller G. Neurodegeneration. Could they all be prion diseases? Science 2009; 326:1337-9; PMID:19965731; http://dx.doi.org/10.1126/science. 326.5958.1337.
51. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 2010; 33:317-25; PMID:20493564; http://dx.doi.org/10.1016/j.tins.2010.04.003.
52. Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 2010; 6:702-6; PMID:21045796; http://dx.doi.org/10.1038/nrneurol. 2010.145.
53. Krammer C, Schätzl HM, Vorberg I. Prion-like propagation of cytosolic protein aggregates: insights from cell culture models. Prion 2009; 3:206-12; PMID:19901539; http://dx.doi.org/10.4161/pri.3.4.10013.
54. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions and prionoids. Neuron 2009; 64:783-90; PMID:20064386; http://dx.doi.org/10.1016/j.neuron.2009.12.016.
55. Iwata A, Maruyama M, Akagi T, Hashikawa T, Kanazawa I, Tsuji S, et al. Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet 2003; 12:2625-35; PMID:12928483; http://dx.doi.org/10.1093/hmg/ddg283.
56. Sung JY, Park SM, Lee CH, Um JW, Lee HJ, Kim J, et al. Proteolytic cleavage of extracellular secreted alpha-synuclein via matrix metalloproteinases. J Biol Chem 2005; 280:25216-24; PMID:15863497; http://dx.doi.org/10.1074/jbc.M503341200.
57. Mishizen-Eberz AJ, Norris EH, Giasson BI, Hodara R, Ischiropoulos H, Lee VM, et al. Cleavage of alphasynuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 2005; 44:7818-29; PMID:15909996; http://dx.doi.org/10.1021/bi047846q.
58. Sevlever D, Jiang P, Yen SH. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 2008; 47:9678-87; PMID:18702517; http://dx.doi.org/10.1021/bi800699v.
59. Kim KS, Choi YR, Park JY, Lee JH, Kim DK, Lee SJ, et al. Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease. J Biol Chem 2012; 287:24862-72; PMID:22619171; http://dx.doi.org/10.1074/jbc.M112.348128.
60. Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, et al. Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci 2000; 54:419-26; PMID:10997858; http://dx.doi.org/10.1046/j.1440-1819.2000. 00731.x.
61. Tatebe H, Watanabe Y, Kasai T, Mizuno T, Nakagawa M, Tanaka M, et al. Extracellular neurosin degrades α-synuclein in cultured cells. Neurosci Res 2010; 67:341-6; PMID:20403393; http://dx.doi.org/10.1016/j.neures.2010.04. 008.
62. Spencer B, Michael S, Shen J, Kosberg K, Rockenstein E, Patrick C, et al. Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wildtype α-Synuclein and Reduces the Pathology in an α-Synuclein Model of LBD. Mol Ther 2012; PMID:22508489; http://dx.doi.org/10.1038/mt.2012.66.
63. Schaller J, Gerber SS. The plasmin-antiplasmin system: structural and functional aspects. Cell Mol Life Sci 2011; 68:785-801; PMID:21136135; http://dx.doi.org/10.1007/s00018-010-0566-5.
64. Dotti CG, Galvan C, Ledesma MD. Plasmin deficiency in Alzheimer's disease brains: causal or casual? Neurodegener Dis 2004; 1:205-12; PMID:16908991; http://dx.doi.org/10.1159/000080987.
65. Syrovets T, Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 2004; 61:873-85; PMID:15095009; http://dx.doi.org/ 10.1007/s00018-003-3348-5.
66. Sheehan JJ, Tsirka SE. Fibrin-modifying serine proteases thrombin, tPA and plasmin in ischemic stroke: a review. Glia 2005; 50:340-50; PMID:15846799; http://dx.doi.org/10.1002/glia.20150.
67. Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 1999; 38:11570-6; PMID:10471309; http://dx.doi.org/10.1021/bi990610f.
68. Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, et al. The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 2000; 20:3937-46; PMID:10818128.
69. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000; 6:143-50; PMID:10655101; http://dx.doi.org/10.1038/77399.
70. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 2000; 1:530-5; PMID:11263499.
71. Backstrom JR, Lim GP, Cullen MJ, Tökés ZA. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 1996; 16:7910-9; PMID:8987819.
72. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998; 273:32730-8; PMID:9830016; http://dx.doi.org/10.1074/jbc.273.49.32730.
73. Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med 2007; 4:e262; PMID:17760499; http://dx.doi.org/10.1371/journal.pmed.0040262.
74. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, et al. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 2008; 105:8754-9; PMID:18559859; http://dx.doi.org/10.1073/pnas.0710823105.
75. Leissring MA. The AbetaCs of Abeta-cleaving proteases. J Biol Chem 2008; 283:29645-9; PMID:18723506; http://dx.doi.org/10.1074/jbc. R800022200.
76. Miners JS, Barua N, Kehoe PG, Gill S, Love S. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 2011; 70:944-59; PMID:22002425; http://dx.doi.org/10.1097/NEN.0b013e3182345e46.
77. Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? J Neurochem 2012; 120(Suppl 1):167-85; PMID:22122230; http://dx.doi.org/10.1111/j.1471-4159.2011. 07510.x.
78. Luhr KM, Nordström EK, Löw P, Ljunggren HG, Taraboulos A, Kristensson K. Scrapie protein degradation by cysteine proteases in CD11c+ dendritic cells and GT1-1 neuronal cells. J Virol 2004; 78:4776-82; PMID:15078959; http://dx.doi.org/10.1128/JVI.78.9.4776-4782.2004.
79. Kim EM, Hwang O. Role of matrix metalloproteinase-3 in neurodegeneration. J Neurochem 2011; 116:22-32; PMID:21044079; http://dx.doi.org/10.1111/j.1471- 4159.2010.07082.x.
80. Joo SH, Kwon KJ, Kim JW, Kim JW, Hasan MR, Lee HJ, et al. Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alphasynuclein in rat primary glial cells. Neurosci Lett 2010; 469:352-6; PMID:20026244; http://dx.doi.org/10.1016/j.neulet.2009.12.026.
81. Kim S, Cho SH, Kim KY, Shin KY, Kim HS, Park CH, et al. Alpha-synuclein induces migration of BV-2 microglial cells by up-regulation of CD44 and MT1-MMP. J Neurochem 2009; 109:1483-96; PMID:19457162; http://dx.doi.org/10.1111/j.1471- 4159.2009.06075.x.
82. Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 2003; 23:8867-71; PMID:14523088.
83. Cacquevel M, Launay S, Castel H, Benchenane K, Chéenne S, Buée L, et al. Ageing and amyloidbeta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms. Neurobiol Dis 2007; 27:164-73; PMID:17566751; http://dx.doi.org/10.1016/j.nbd. 2007.04.004.
84. Sutton R, Keohane ME, VanderBerg SR, Gonias SL. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis 1994; 5:167-71; PMID:8054448; http://dx.doi.org/10. 1097/00001721-199404000-00002.
85. Kornblatt JA, Marchal S, Rezaei H, Kornblatt MJ, Balny C, Lange R, et al. The fate of the prion protein in the prion/plasminogen complex. Biochem Biophys Res Commun 2003; 305:518-22; PMID:12763023; http://dx.doi.org/10.1016/S0006- 291X(03)00804-0.
86. Apelt J, Ach K, Schliebs R. Aging-related downregulation of neprilysin, a putative beta-amyloiddegrading enzyme, in transgenic Tg2576 Alzheimerlike mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci Lett 2003; 339:183-6; PMID:12633883; http://dx.doi.org/10.1016/S0304-3940(03)00030-2.
87. Ferretti MT, Partridge V, Leon WC, Canneva F, Allard S, Arvanitis DN, et al. Transgenic mice as a model of pre-clinical Alzheimer's disease. Curr Alzheimer Res 2011; 8:4-23; PMID:21143159; http://dx.doi.org/10.2174/ 156720511794604561.
88. Nalivaevaa NN, Fisk L, Kochkina EG, Plesneva SA, Zhuravin IA, Babusikova E, et al. Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid-degrading enzymes. Ann N Y Acad Sci 2004; 1035:21-33; PMID:15681798; http://dx.doi.org/10.1196/annals.1332.002.
89. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46:857-68; PMID:15953415; http://dx.doi.org/10.1016/j. neuron.2005.05.010.
90. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011; 6:e19338; PMID:21559417; http://dx.doi.org/10.1371/journal.pone.0019338.
91. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, et al. Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 2011; 25:326-36; PMID:20876215; http://dx.doi.org/10.1096/fj.10-164624.
92. Kurz A, Perneczky R. Amyloid clearance as a treatment target against Alzheimer's disease. J Alzheimers Dis 2011; 24(Suppl 2):61-73; PMID:21422524.
93. Sokolowski JD, Mandell JW. Phagocytic clearance in neurodegeneration. Am J Pathol 2011; 178:1416-28; PMID:21435432; http://dx.doi.org/10.1016/j.ajpath. 2010.12.051.
94. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010; 6:108-19; PMID:20140000; http://dx.doi.org/10.1038/nrneurol.2009.219.
95. Sadowski MJ, Pankiewicz J, Prelli F, Scholtzova H, Spinner DS, Kascsak RB, et al. Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis 2009; 34:267-78; PMID:19385058; http://dx.doi.org/10.1016/j.nbd. 2009.01.013.
96. Götz J, Ittner A, Ittner LM. Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol 2012; 165:1246-59; PMID:22044248; http://dx.doi.org/10.1111/j.1476-5381.2011.01713.x.
97. Gros-Louis F, Soucy G, Larivière R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010; 113:1188-99; PMID:20345765.
98. Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2007; 104:2495-500; PMID:17277077; http://dx.doi.org/10.1073/pnas.0606201104.